PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00143312
- Locations
- π¬π§
Pfizer Investigational Site, Manchester, United Kingdom
Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00143169
- Locations
- π¨π³
Pfizer Investigational Site, Shanghai, China
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00143091
- Locations
- π·πΊ
Pfizer Investigational Site, St.-Petersburg, Russian Federation
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00143338
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Long Term Study With B2036-PEG
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00143416
- Locations
- π―π΅
Pfizer Investigational Site, Sannomaru-cho, Naka-ku, Nagoya-shi, Japan
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT00143117
- Locations
- πΊπΈ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00141284
- Locations
- π¨π¦
Pfizer Investigational Site, Toronto, Ontario, Canada
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT00141661
- Locations
- πΊπΈ
Pfizer Investigational Site, Memphis, Tennessee, United States
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1005
- Registration Number
- NCT00141206
- Locations
- πΊπΈ
Pfizer Investigational Site, Morgantown, West Virginia, United States
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 325
- Registration Number
- NCT00141362
Β© Copyright 2024. All Rights Reserved by MedPath